Effect of rimantadine treatment on clinical manifestations and otologic complications in adults experimentally infected with influenza A (H1N1) virus.
Susceptible adults (n = 105) were enrolled into a randomized double-blind study of rimantadine treatment of experimental influenza A infection. Subjects were cloistered for 8 days and challenged with a rimantadine-sensitive strain of influenza A H1N1 virus at the end of the first day. Forty-eight hours after challenge and for 8 days, 54 subjects received placebo and 51 received rimantadine (100 mg orally, twice a day). Symptoms, signs, and pathophysiologies were monitored. Nine subjects were not infected. Seventeen subjects (38%) in the rimantadine and 26 (53%) in the placebo group became ill. A beneficial effect of rimantadine was documented for virus shedding, symptom load, and sinus pain. Rimantadine had no effect on nasal patency, mucociliary clearance, nasal signs, or on symptoms and signs of otologic complications. These results do not support a preventive effect of rimantadine on the development of otologic manifestations of influenza A infection in adults.
Doyle
W J
WJ
Department of Otolaryngology, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pennsylvania 15213, USA.
Skoner
D P
DP
Alper
C M
CM
Allen
G
G
Moody
S A
SA
Seroky
J T
JT
Hayden
F G
FG
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype; D009980:Influenza A virus / Q000302:isolation & purification; D007251:Influenza, Human / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D008875:Middle Aged; D010033:Otitis Media / Q000453:epidemiology*; D010146:Pain; D010919:Placebos; D012299:Rimantadine / Q000627:therapeutic use*; D013997:Time Factors; D017201:Virus Shedding
D000998:Antiviral Agents; D010919:Placebos; D012299:Rimantadine